ALERT: Stay healthy this cold and flu season! Learn more
ALERTA: ¡Mantente sano durante esta temporada de influenza y resfriados! Más información
Removal of Certain Drugs from the TMPPM
Date: May 23, 2025
Attention: All Providers
Effective Date: June 1, 2025
Call to action: The purpose of this communication is to inform providers that on June 1, 2025, Texas Medicaid & Healthcare Partnership (TMHP) will remove the following subsections from the Texas Medicaid Provider Procedures Manual (TMPPM), Outpatient Drug Services Handbook:
- Subsection 6.18, “Brexanolone (Zulresso)” – procedure code J1632 will no longer have a rebate-eligible National Drug Code (NDC), effective June 1, 2025.
- Subsection 6.77, “Lefamulin (Xenleta)” – procedure code J0691 currently does not have a rebate-eligible NDC.
- Subsection 6.91, “Moxetumomab Pasudotox-tdfk (Lumoxiti)” – procedure code J9313 will no longer have a rebate-eligible NDC, effective June 1, 2025.
These drugs are not covered on the Texas Medicaid benefit.
Next steps: Providers are encouraged to share this communication with their staff.
If you have any questions, please email Provider Relations at: providerrelations@texaschildrens.org.
For access to all provider alerts,log into:
www.texaschildrenshealthplan.org/provideralerts.